04.04.13
X-BODY Biosciences has entered an exclusive alliance with Jiangsu Hengrui Medicine Co. under which Hengrui will develop and commercialize a novel antibody program generated from X-BODY's antibody platform for Age-related Macular Degeneration (AMD) in China (including, Taiwan, Macao, and Hong Kong).
Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts. X-BODY retains all development and commercialization rights outside Greater China. Financial terms were not disclosed, but terms of the alliance include an upfront payment, clinical, regulatory and commercialization milestones, and royalties on sales.
"It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY," said Lianshan Zhang, Ph.D., president of Global R&D, Jiangsu Hengrui Medicine Co.
"This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform. We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients' lives, especially for a disease as life-altering as AMD," said Julius Knowles, chief executive officer of X-BODY.
Hengrui will fund and lead all preclinical and clinical development, as well as commercialization efforts. X-BODY retains all development and commercialization rights outside Greater China. Financial terms were not disclosed, but terms of the alliance include an upfront payment, clinical, regulatory and commercialization milestones, and royalties on sales.
"It is an important part of our corporate strategy to partner with biotechs around the world that could provide interesting molecules for us to develop and commercialize, and we are excited to take on board the first of hopefully many development programs from X-BODY," said Lianshan Zhang, Ph.D., president of Global R&D, Jiangsu Hengrui Medicine Co.
"This collaboration with Hengrui, the clear leader in pharmaceutical development in China, is an important step on our path to validate the capabilities of our DNA Display drug discovery platform. We are encouraged to see our platform yield antibodies that could have a meaningful impact on patients' lives, especially for a disease as life-altering as AMD," said Julius Knowles, chief executive officer of X-BODY.